Literature DB >> 16157897

Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

David K Chen1, Yuen T So, Robert S Fisher.   

Abstract

OBJECTIVE: The purpose of this article is to review the use of serum prolactin assay in epileptic seizure diagnosis.
METHODS: The authors identified relevant studies in multiple databases and reference lists. Studies that met inclusion criteria were summarized and rated for quality of evidence, and the results were analyzed and pooled where appropriate.
RESULTS: Most studies used a serum prolactin of at least twice baseline value as abnormal. For the differentiation of epileptic seizures from psychogenic nonepileptic seizures, one Class I and seven Class II studies showed that elevated serum prolactin was highly predictive of either generalized tonic-clonic or complex partial seizures. Pooled sensitivity was higher for generalized tonic-clonic seizures (60.0%) than for complex partial seizures (46.1%), while the pooled specificity was similar for both (approximately 96%). Data were insufficient to establish validity for simple partial seizures. Two Class II studies were consistent in showing prolactin elevation after tilt-test-induced syncope. Inconclusive data exist regarding the value of serum prolactin following status epilepticus, repetitive seizures, and neonatal seizures. RECOMMENDATIONS: Elevated serum prolactin assay, when measured in the appropriate clinical setting at 10 to 20 minutes after a suspected event, is a useful adjunct for the differentiation of generalized tonic-clonic or complex partial seizure from psychogenic nonepileptic seizure among adults and older children (Level B). Serum prolactin assay does not distinguish epileptic seizures from syncope (Level B). The use of serum PRL assay has not been established in the evaluation of status epilepticus, repetitive seizures, and neonatal seizures (Level U).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157897     DOI: 10.1212/01.wnl.0000178391.96957.d0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures.

Authors:  W C LaFrance; K Leaver; E G Stopa; G D Papandonatos; A S Blum
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

2.  Serum neuron-specific enolase level as a biomarker in differential diagnosis of seizure and syncope.

Authors:  Seung-Yeob Lee; Young-Chul Choi; Jeong-Ho Kim; Won-Joo Kim
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

3.  Is prolactin a clinically useful measure of epilepsy?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2006 May-Jun       Impact factor: 7.500

4.  Serum NT-pro CNP levels in epileptic seizure, psychogenic non-epileptic seizure, and healthy subjects.

Authors:  Mustafa Ceylan; Ahmet Yalcin; Omer Faruk Bayraktutan; Esra Laloglu
Journal:  Neurol Sci       Date:  2018-09-19       Impact factor: 3.307

5.  Postictal ammonia as a biomarker for electrographic convulsive seizures: A prospective study.

Authors:  Rawan Albadareen; Gary Gronseth; Patrick Landazuri; Jianghua He; Nancy Hammond; Utku Uysal
Journal:  Epilepsia       Date:  2016-06-01       Impact factor: 5.864

6.  Serum prolactin in seizure diagnosis: Glass half-full or half-empty?

Authors:  Robert S Fisher
Journal:  Neurol Clin Pract       Date:  2016-04

Review 7.  Neuroendocrine considerations in the treatment of men and women with epilepsy.

Authors:  Cynthia L Harden; Page B Pennell
Journal:  Lancet Neurol       Date:  2013-01       Impact factor: 44.182

8.  How to Use Your Clinical Judgment to Screen for and Diagnose Psychogenic Nonepileptic Seizures without Video Electroencephalogram.

Authors:  Shahid Ali; Shagufta Jabeen; Amir Arain; Tamer Wassef; Ahmed Ibrahim
Journal:  Innov Clin Neurosci       Date:  2011-01

9.  Seizures and epilepsy in the acute medical setting: presentation and management.

Authors:  Elizabeth Caruana Galizia; Howard John Faulkner
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

Review 10.  [Management of refractory status epilepticus from a neurologic and neuropediatric perspective].

Authors:  B Pohlmann-Eden; U Stephani; I Krägeloh-Mann; B Schmitt; U Brandl; M Holtkamp
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.